BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.25 ^USD	+1.63%		-8.76%	-28.16%

Apr. 16	BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	DJ
Apr. 16	BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	MT

BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 27, 2023 at 06:13 am EDT

BioRestorative Therapies, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.1198 million compared to USD 0.046 million a year ago. Net loss was USD 18.49 million compared to USD 44.3 million a year ago.

Basic loss per share from continuing operations was USD 5.11 compared to USD 37.3 a year ago. Diluted loss per share from continuing operations was USD 5.11 compared to USD 37.3 a year ago.

Latest news about BioRestorative Therapies, Inc.

BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	Apr. 16	DJ
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	Apr. 16	MT
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	Apr. 16	CI
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	Apr. 08	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	Feb. 14	CI
Top Midday Decliners	Feb. 06	MT
Top Premarket Decliners	Feb. 06	MT
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise	Feb. 05	MT
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	Feb. 05	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-18	MT
Sector Update: Health Care Stocks Mixed Monday Afternoon	23-09-18	MT
Sector Update: Health Care	23-09-18	MT
BioRestorative Therapies Shares Rise After Shareholder Broadrick Dale Boosts Stake	23-09-18	MT
Biorestorative Therapies Enters into Supply Agreement with Evolutionary Biologics	23-09-12	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
BioRestorative Therapies Secures New York State License to Operate as Tissue Bank	23-07-21	MT
Biorestorative Therapies Inc. Receives License from New York State	23-07-21	CI
BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding	23-07-10	CI
BioRestorative Therapies Says Lumbar Disc Disease Treatment Recommended to Continue Phase 2 Trial	23-07-07	MT
BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100	23-07-07	CI
BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program	23-05-15	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial	23-05-08	CI

Chart BioRestorative Therapies, Inc.

Duration

Period

More charts

Company Profile

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for BioRestorative Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.25 USD

Average target price

10.5 USD

Spread / Average Target

+740.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIORESTORATIVE THERAPIES, INC.	-28.16%	8.46M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs